Regenxbio Inc (NASDAQ: RGNX) kicked off on Friday, down -5.76% from the previous trading day, before settling in for the closing price of $14.4. Over the past 52 weeks, RGNX has traded in a range of $5.03-$15.41.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -12.18%. While this was happening, its average annual earnings per share was recorded 32.89%. With a float of $46.14 million, this company’s outstanding shares have now reached $50.62 million.
Regenxbio Inc (RGNX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 8.86%, while institutional ownership is 81.43%. The most recent insider transaction that took place on Oct 09 ’25, was worth 262,635. In this transaction Chief Executive Officer of this company sold 20,811 shares at a rate of $12.62, taking the stock ownership to the 216,162 shares. Before that another transaction happened on Oct 09 ’25, when Company’s Director proposed sale 20,811 for $12.22, making the entire transaction worth $254,310.
Regenxbio Inc (RGNX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.01 earnings per share (EPS), higher than consensus estimate (set at -1.08) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.98% during the next five years compared to -12.18% drop over the previous five years of trading.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Take a look at Regenxbio Inc’s (RGNX) current performance indicators. Last quarter, stock had a quick ratio of 2.66. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.49, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -1.87 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
As of the previous 9 days, the stock’s Stochastic %D was 45.00%.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 76.64%, which indicates a significant increase from 32.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.97 in the past 14 days, which was higher than the 0.71 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.79, while its 200-day Moving Average is $9.85. Now, the first resistance to watch is $14.51. This is followed by the second major resistance level at $15.45. The third major resistance level sits at $16.25. If the price goes on to break the first support level at $12.77, it is likely to go to the next support level at $11.97. Assuming the price breaks the second support level, the third support level stands at $11.03.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
The company with the Market Capitalisation of 686.96 million has total of 50,623K Shares Outstanding. Its annual sales at the moment are 83,330 K in contrast with the sum of -227,100 K annual income. Company’s last quarter sales were recorded 29,730 K and last quarter income was -61,940 K.
